Filing Details

Accession Number:
0001714899-23-000055
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-14 18:27:13
Reporting Period:
2023-04-12
Accepted Time:
2023-04-14 18:27:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724311 O. Alexander Schuth C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Cofo And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-12 5,102 $5.28 533,793 No 4 M Indirect See footnote
Common Stock Disposition 2023-04-12 5,102 $25.04 528,691 No 4 S Indirect See footnote
Common Stock Acquisiton 2023-04-13 4,898 $5.28 533,589 No 4 M Indirect See footnote
Common Stock Disposition 2023-04-13 4,898 $25.04 528,691 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect See footnote
No 4 S Indirect See footnote
No 4 M Indirect See footnote
No 4 S Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-04-12 5,102 $0.00 5,102 $5.28
Common Stock Stock Option (right to buy) Disposition 2023-04-13 4,898 $0.00 4,898 $5.28
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
93,835 2027-03-07 No 4 M Direct
88,937 2027-03-07 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 130,792 Direct
Footnotes
  1. Exercised shares were issued to the Schuth Family Trust.
  2. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
  3. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.
  4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  6. Includes 119,156 RSUs.
  7. 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.